logo
Plus   Neg
Share
Email

Stage Stores Projects FY19 Comps. To Rise 1%-3%; Q2 Comps. Up 1.8% - Quick Facts

Stage Stores, Inc. (SSI), announced, for 2019, the company now expects adjusted EBITDA of $20 million to $25 million compared to the previously guided range of $10 million to $15 million. The company said the guidance revision is based on its accelerated conversion schedule and significant SG&A benefits now expected to be realized in the fall of 2019. For 2019, the revised comparable sales growth outlook is in the range of 1% to 3%. Net sales are projected to be in the range of $1.56 billion and $1.59 billion.

For the second quarter, loss per share was $0.83 compared to loss per share of $0.60, previous year. Adjusted EBITDA was a loss of $0.1 million compared to adjusted EBITDA of $2.0 million.

Second-quarter net sales were $368 million compared to $369 million, previous year. Comparable sales increased 1.8%, for the quarter.

Michael Glazer, CEO, said: "Our second quarter comparable sales increase reflects a 150 basis point benefit from off-price conversions as well as stabilization of our women's apparel business. Total comparable sales growth was driven by increases in both average transaction value and number of transactions."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill Inc. is introducing a new protein to its menu, Carne Asada, starting this week. Carne Asada is Chipotle's newest protein addition since it reintroduced chorizo in September 2018. The Mexican food chain said that the new steak option will be available at its restaurants nationwide from Thursday, September 19, 2019. Pizza Hut has partnered with Cheez-It to launch a new item to its menu - the Stuffed Cheez-It Pizza. The pizza chain, a subsidiary of Yum! Brands, said that the new item combines Pizza Hut pizza and the Cheez-It cheese snack. Stuffed Cheez-It Pizza will be available on Pizza Hut menus nationwide for a limited-time. Pizza Hut is the official pizza sponsor of the NFL and NCAA. The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world.
Follow RTT